“…Furthermore, Abraxane® promoted higher tumor accumulation of paclitaxel (~33%), inhibited elimination (4-fold decrease) [37] , and demonstrated a superior overall response rate (34%) compared to paclitaxel (19%) in patients with advanced breast cancer [38] , [58] . Importantly, combination therapies of Abraxane® with conventional chemotherapeutic agents and targeted therapies have also demonstrated safety and superior efficacy compared to single therapies in clinical trials [52] , [53] . Lipusu® (China, 2003) was the first liposomal formulation of paclitaxel approved for the treatment of non-small lung cancer, ovarian, and breast cancer [41] , [42] , [51] , [56] .…”